Clinical Research Directory

Inclusion Criteria: 1. Patients with LVEF \</= 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy. 2. Age \>/= 18 and \</= 90 years of age. English and non-English speaking patients are eligible. 3. Documented NYHA class I, II and III. 4. For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab. 5. Able to perform 6 minute walk test. 6. Been treated with appropriate maximal medical therapy for heart failure. 7. Patient or legally authorized representative able to sign informed consent. Exclusion Criteria: 1. Evidence of Ischemic Heart Disease as determined by study cardiologist. 2. Significant Valvular Disease. (AS with AVA \<1.5 and severe AR and MR) 3. History of Familial Cardiomyopathy. 4. Recent documented myocarditis within 2 months of enrollment. 5. History of Infiltrative cardiomyopathy or restrictive cardiomyopathy. 6. Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram. 7. Liver function tests \> 3 x upper limit of normal. 8. NYHA class IV heart failure. 9. Inotropic dependence. 10. Unstable or life-threatening arrhythmia. 11. For patients not on anticoagulants, INR\>1.5 12. Mechanical or Bioprosthetic heart valve. 13. Cardiogenic shock. 14. Breastfeeding and/or pregnant women. 15. Autoimmune disorders on current immunosuppressive therapy. 16. Active infection not responding to appropriate therapy as determined by Study Chair. 17. Trastuzumab treatment within the last 3 months. 18. Automatic implantable cardioverter defibrillator (AICD) placement within the last 30 days. 19. AICD firing within the last 30 days.